Propanc's Lead Asset Prp Achieves >85% Tumor Inhibition in Pancreatic Cancer Preclinical Study
PPCB sits 48% above its 52-week low of $0.156 on light trading volume (0.2× avg).
Summary
Propanc Biopharma announced that its lead asset, Prp, demonstrated over 85% tumor growth inhibition in preclinical models for pancreatic cancer. This positive development provides a significant boost to the company's product pipeline, especially following the recent 10-Q filing on February 17th which highlighted substantial net losses, cash burn, and a going concern warning. The strong preclinical data for Prp, combined with the recent appointment of an experienced oncology executive, Dr. Ralf Brandt, on February 26th, suggests a renewed focus on advancing its core therapeutic candidates. While still in preclinical stages, these results offer a potential future path for the company and could attract investor interest despite its current financial challenges. Investors will now watch for further updates on Prp's progression towards clinical trials.
At the time of this announcement, PPCB was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.16 to $24.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.